Trade-Ideas LLC identified Biogen Idec ( BIIB) is one of the leading pre-market leader candidate. They recognized Bioden as a stock because of the following:

BIIB has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $781.2 million.

BIIB traded 60,721 shares today in the pre-market hours as of 7:33 AM.

BIIB is up 4% today from yesterday’s close.

More details on BIIB:

Biogen Idec Inc. finds out, creates, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. BIIB has a PE ratio of 34.5. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for Biogen Idec has been 1.6 million shares per day over the past 30 days. Biogen Idec has a market cap of $100.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.62 and a short float of 1.6% with 1.97 days to cover. Shares are up 26.1% year-to-date as of the close of trading on Wednesday.

TheStreetRatings Analysis:

TheStreet Quant Ratings rates Biogen Idec as a buy. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:

Despite its growing revenue, the company underperformed as compared with the industry average of 36.4%. Since the same quarter one year prior, revenues rose by 34.3%. Growth in the company’s revenue appears to have helped boost the earnings per share.

BIIB’s debt-to-equity ratio is very low at 0.05 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, BIIB has a quick ratio of 1.54, which demonstrates the ability of the company to cover short-term liquidity needs.

Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. When compared to other companies in the Biotechnology industry and the overall market, BIOGEN IDEC INC’s return on equity exceeds that of the industry average and significantly exceeds that of the S&P 500.

The gross profit margin for BIOGEN IDEC INC is currently very high, coming in at 90.65%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 33.45% is above that of the industry average.